+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years - 75Years
All Genders
ID07106736

Evaluating MRD-Guided Immunotherapy with BCMA CAR-T and Bispecific Antibody Treatment in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Patients

Led by Institute of Hematology & Blood Diseases Hospital, China · Updated on 2026-10-27

60

Participants Needed

1

Research Sites

104 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating a fully immunotherapy-based strategy guided by minimal residual disease MRD to dynamically stratify risk in patients newly diagnosed with multiple myeloma who cannot undergo transplant. This Phase 2 clinical study aims to assess the safety and effectiveness of this approach in transplant-ineligible patients, using MRD status to guide treatment decisions based on risk groups. All participants first receive standard induction treatment for up to four cycles. After response evaluation, patients are divided into standard-risk and ultra-high-risk groups based on specific clinical and molecular characteristics. Standard-risk patients receive a single-dose infusion of BCMA CAR-T therapy followed by standard consolidation and maintenance. Ultra-high-risk patients also receive BCMA CAR-T therapy but then receive GPRC5DCD3 bispecific antibody therapy for consolidation and maintenance. Those achieving sustained MRD negativity and stringent complete response may enter a treatment-free observation phase, with maintenance therapy resuming if MRD returns or response is lost. Participants are closely monitored through consecutive assessments of MRD and response status, with safety and efficacy outcomes measured over up to two years for MRD negativity and complete response, and up to five years for overall survival. The study tracks progression-free survival alongside these outcomes. The total participation duration can extend up to four years, including treatment, observation, and follow-up phases to evaluate long-term effects and disease control.

CONDITIONS

Brief Title

MRD-Adaptive Guided Immunotherapy With CAR-T for Transplant-Ineligible Patients With Multiple Myeloma

Research Team

G

Gang An, PhD&MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here